-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-28
IFRX:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.7305Change
-1.09 (-59.86)%Market Cap
USD 0.11BVolume
8.16MVerdict
Verdict
Values as of: 2025-05-28
COMMON STOCK | Biotechnology |
Last Closing
USD 0.7305Change
-1.09 (-59.86)%Market Cap
USD 0.11BVolume
8.16MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
+1.99 (+0.45%) |
USD 128.84B |
REGN | Regeneron Pharmaceuticals Inc |
+13.54 (+2.29%) |
USD 65.38B |
ARGX | argenx NV ADR |
+4.71 (+0.82%) |
USD 34.54B |
ALNY | Alnylam Pharmaceuticals Inc |
+7.34 (+2.57%) |
USD 32.75B |
ONC | BeiGene, Ltd. |
+6.27 (+2.61%) |
USD 27.70B |
SMMT | Summit Therapeutics PLC |
+0.17 (+0.65%) |
USD 27.07B |
RPRX | Royalty Pharma Plc |
+0.01 (+0.03%) |
USD 18.40B |
INSM | Insmed Inc |
+2.85 (+4.29%) |
USD 11.84B |
INCY | Incyte Corporation |
+1.11 (+1.71%) |
USD 11.42B |
BMRN | Biomarin Pharmaceutical Inc |
+0.46 (+0.79%) |
USD 11.29B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
ZEO:CA | BMO Equal Weight Oil & Ga.. | 8.72 % | 0.61 % |
-0.15 (-0.36%) |
CAD 0.21B |
NRGY:CA | Global X Equal Weight Can.. | 8.69 % | 0.00 % |
-0.07 (-0.36%) |
CAD 0.22B |
XEG:CA | iShares S&P/TSX Capped En.. | 6.10 % | 0.61 % |
+0.01 (+-0.36%) |
CAD 1.60B |
ENCC:CA | Global X Canadian Oil and.. | 5.23 % | 0.00 % |
+0.01 (+-0.36%) |
CAD 0.51B |
PWER | Macquarie ETF Trust | 4.31 % | 0.00 % |
-0.03 (-0.36%) |
USD 6.78M |
XMD:CA | iShares S&P/TSX Completio.. | 2.25 % | 0.61 % |
-0.13 (-0.36%) |
CAD 0.28B |
VSS | Vanguard FTSE All-World e.. | 0.33 % | 0.12 % |
+0.54 (+-0.36%) |
USD 8.76B |
ENY | 0.00 % | 0.66 % |
N/A |
N/A | |
FQC:CA | 0.00 % | 1.01 % |
N/A |
N/A | |
HEE:CA | 0.00 % | 0.84 % |
N/A |
N/A | |
SCHC | Schwab International Smal.. | 0.00 % | 0.12 % |
+0.16 (+-0.36%) |
N/A |
ZJO:CA | 0.00 % | 0.60 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -70.43% | 10% | F | 5% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -70.43% | 9% | A- | 5% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -49.97% | 43% | F | 19% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -49.97% | 43% | F | 19% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -91.72% | 33% | F | 10% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -91.72% | 33% | F | 10% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -5.50% | 48% | F | 30% | F | ||
Dividend Return | -5.50% | 48% | F | 29% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 72.61% | 47% | F | 25% | F | ||
Risk Adjusted Return | -7.58% | 48% | F | 33% | F | ||
Market Capitalization | 0.11B | 51% | F | 40% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total earnings in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.